Who are Clopidogrel and proton pump inhibitors's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/clopidogrel-and-proton-pump-inhibitors.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Clopidogrel and proton pump inhibitors — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clopidogrel and proton pump inhibitors (Clopidogrel and proton pump inhibitors) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent (thienopyridine) with drug-drug interaction study. Area: Cardiovascular.

marketed Antiplatelet agent (thienopyridine) with drug-drug interaction study P2Y12 receptor (clopidogrel); CYP2C19 enzyme (PPI interaction) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Clopidogrel and proton pump inhibitors (Clopidogrel and proton pump inhibitors) — National Taiwan University Hospital. Clopidogrel is a P2Y12 inhibitor that reduces platelet aggregation, but proton pump inhibitors impair its activation, reducing its antiplatelet efficacy.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Clopidogrel and proton pump inhibitors TARGET	Clopidogrel and proton pump inhibitors	National Taiwan University Hospital	marketed	Antiplatelet agent (thienopyridine) with drug-drug interaction study	P2Y12 receptor (clopidogrel); CYP2C19 enzyme (PPI interaction)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent (thienopyridine) with drug-drug interaction study class)

National Taiwan University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Clopidogrel and proton pump inhibitors — Competitive Intelligence Brief. https://druglandscape.com/ci/clopidogrel-and-proton-pump-inhibitors. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab